Porocarcinoma with YAP1‐NUTM1 fusion presenting as a NUT immunohistochemistry‐positive lymph node metastasis

Porocarcinoma is a rare, malignant adnexal tumor that recently has been shown to contain YAP1‐NUTM1 and YAP1‐MAML2 fusion transcripts, with nuclear protein in testis (NUT) immunohistochemistry (IHC) positivity in a subset of these tumors. Consequently, NUT IHC may either aid in the differential diagnosis, or represent a confounding factor depending on the clinical scenario. Here, we present a case of NUTM1‐rearranged sarcomatoid porocarcinoma of the scalp presenting as a NUT IHC‐positive lymph node metastasis.

[1]  P. Stafford,et al.  NUTM1-Rearranged Neoplasms—A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations—An Updated Review , 2021, Current oncology.

[2]  J. Swensen,et al.  Poroid adnexal skin tumors with YAP1 fusions exhibit similar histopathologic features: A series of six YAP1‐rearranged adnexal skin tumors , 2021, Journal of cutaneous pathology.

[3]  J. Lehmann-Che,et al.  NUT Is a Specific Immunohistochemical Marker for the Diagnosis of YAP1-NUTM1-rearranged Cutaneous Poroid Neoplasms , 2021, The American journal of surgical pathology.

[4]  J. Hornick,et al.  Utility of YAP1 and NUT immunohistochemistry in the diagnosis of porocarcinoma , 2020, Journal of cutaneous pathology.

[5]  J. Bridge,et al.  A case of YAP1 and NUTM1 rearranged porocarcinoma with corresponding immunohistochemical expression: Review of recent advances in poroma and porocarcinoma pathogenesis with potential diagnostic utility , 2020, Journal of cutaneous pathology.

[6]  R. Seemann,et al.  Eccrine porocarcinoma of the head and neck: Meta‐analysis of 120 cases , 2020, Head & neck.

[7]  F. Samie,et al.  Demographics and outcomes of eccrine porocarcinoma: results from the National Cancer Database , 2020, The British journal of dermatology.

[8]  S. Sallan,et al.  An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients , 2019, JNCI cancer spectrum.

[9]  K. Tsuta,et al.  Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. , 2019, The Journal of clinical investigation.

[10]  A. Wysong,et al.  Eccrine Porocarcinoma: New Insights and a Systematic Review of the Literature , 2018, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[11]  Yingming Zhao,et al.  Nut Directs p300-Dependent, Genome-Wide H4 Hyperacetylation in Male Germ Cells. , 2018, Cell reports.

[12]  D. Cassarino,et al.  Biphasic Sarcomatoid Porocarcinoma , 2016, The American Journal of dermatopathology.

[13]  B. Beverloo,et al.  NUT Midline Carcinoma of the Parotid Gland With Mesenchymal Differentiation , 2009, The American journal of surgical pathology.

[14]  C. French.  Demystified molecular pathology of NUT midline carcinomas , 2008, Journal of Clinical Pathology.

[15]  J. Carlson,et al.  Cutaneous carcinosarcoma: adnexal vs. epidermal types define high‐ and low‐risk tumors. Results of a meta‐analysis , 2005, Journal of cutaneous pathology.

[16]  J. Fletcher,et al.  BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. , 2003, Cancer research.

[17]  U. Kees,et al.  Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19). , 1991, The American journal of pediatric hematology/oncology.